Evidence map›Paper›PMID 36927444›Full record

ArticleBMC bioinformatics2023

Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine.

Shaima Belhechmi, Gwénaël Le Teuff, Riccardo De Bin, Federico Rotolo, Stefan Michiels

Open access · goldFull text read
In one paragraph

Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Shaima BelhechmiUniversité Paris-Saclay, CESP, INSERM U1018 Oncostat, labeled Ligue Contre le Cancer, Villejuif, France.
Gwénaël Le TeuffUniversité Paris-Saclay, CESP, INSERM U1018 Oncostat, labeled Ligue Contre le Cancer, Villejuif, France.
Riccardo De BinDepartment of Mathematics, University of Oslo, Oslo, Norway.
Federico RotoloBiostatistics and Data Management Unit, Innate Pharma, Marseille, France.
Stefan MichielsUniversité Paris-Saclay, CESP, INSERM U1018 Oncostat, labeled Ligue Contre le Cancer, Villejuif, France. Stefan.MICHIELS@gustaveroussy.fr.
La Ligue Contre le Cancer · FRInnate Pharma (France) · FRInstitut Gustave Roussy · FRUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe research of biomarker-treatment interactions is commonly investigated in randomized clinical trials (RCT) for improving medicine precision. The hierarchical interaction constraint states that an interaction should only be in a model if its main effects are also in the model. However, this constraint is not guaranteed in the standard penalized statistical approaches. We aimed to find a compromise for high-dimensional data between the need for sparse model selection and the need for the hierarchical constraint.

resultsTo favor the property of the hierarchical interaction constraint, we proposed to create groups composed of the biomarker main effect and its interaction with treatment and to perform the bi-level selection on these groups. We proposed two weighting approaches (Single Wald (SW) and likelihood ratio test (LRT)) for the adaptive lasso method. The selection performance of these two approaches is compared to alternative lasso extensions (adaptive lasso with ridge-based weights, composite Minimax Concave Penalty, group exponential lasso and Sparse Group Lasso) through a simulation study. A RCT (NSABP B-31) randomizing 1574 patients (431 events) with early breast cancer aiming to evaluate the effect of adjuvant trastuzumab on distant-recurrence free survival with expression data from 462 genes measured in the tumour will serve for illustration. The simulation study illustrates that the adaptive lasso LRT and SW, and the group exponential lasso favored the hierarchical interaction constraint. Overall, in the alternative scenarios, they had the best balance of false discovery and false negative rates for the main effects of the selected interactions. For NSABP B-31, 12 gene-treatment interactions were identified more than 20% by the different methods. Among them, the adaptive lasso (SW) approach offered the best trade-off between a high number of selected gene-treatment interactions and a high proportion of selection of both the gene-treatment interaction and its main effect.

conclusionsAdaptive lasso with Single Wald and likelihood ratio test weighting and the group exponential lasso approaches outperformed their competitors in favoring the hierarchical constraint of the biomarker-treatment interaction. However, the performance of the methods tends to decrease in the presence of prognostic biomarkers.

Indexed as

Breast NeoplasmsPrecision MedicineBiomarkersComputer SimulationFemaleHumansRandomized Controlled Trials as TopicBiomarkersBiomarker selectionBiomarker-treatment interactionsCox regressionHierarchical interactionLassoPrecision medicine

Identifiers

PMID36927444
PMCPMC10022294
OpenAlexW4327676970

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read61
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.